FDA approval of obesity drugs: a difference in risk-benefit perceptions.

@article{Morrato2012FDAAO,
  title={FDA approval of obesity drugs: a difference in risk-benefit perceptions.},
  author={Elaine H. Morrato and David B. Allison},
  journal={JAMA},
  year={2012},
  volume={308 11},
  pages={1097-8}
}
Given the obesity epidemic, patients and physicians are clamoring for new treatments. Companies are responding with significant investment in drug development. Drugs provide an important therapeutic option when lifestyle modifications are insufficient for achieving weight loss goals and when surgery is not desired or warranted. However, in the last decade, three obesity drugs were removed from the U.S. market and until last month, only one new obesity drug has been approved since 1999. How is… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
6 Citations
6 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-6 of 6 references

and Drug Administration

  • U. S. Foo
  • [Accessed July 18,
  • 2012
1 Excerpt

Dichotomous and Complex Thinking

  • SB Berlin
  • Social Service Review
  • 1990

Science . 1987 Perception of risk

  • P Slovic

Similar Papers

Loading similar papers…